Evidence map›Paper›PMID 37479526›Full record

ArticleBMJ open2023

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for

Yaoyi Wu, Yujing Wang, Xiaochen Liu, Oulan Liao, Guochun Lou, Yan Li, Hao Wu, Qin Du, Jun Ye

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05718609 (Efficacy of Quadruple Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests as First-line Treatment for Helicobacter Pylori Infection), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05718609 phase4unknown statusnot on this map

Efficacy of Quadruple Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests as First-line Treatment for Helicobacter Pylori Infection

TypeinterventionalSponsorSecond Affiliated Hospital, Zhejiang University, School of MedicineRan2023 to 2024Enrolled855ConditionsHelicobacter Pylori InfectionArmsRabeprazole, Colloidal Bismuth Pectin Granules, Amoxicillin, Furazolidone, Clarithromycin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yaoyi WuDepartment of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China.
Yujing WangDepartment of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China.
Xiaochen LiuDepartment of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China.
Oulan LiaoDepartment of Gastroenterology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, Zhejiang, China.
Guochun LouDepartment of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China.
Yan LiDepartment of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China.
Hao WuCancer Institute (Key Laboratory for Cancer Intervention and Prevention, China National Ministry of Education, Zhejiang Provincial Key Laboratory of Molecular Biology in Medical Sciences), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China wzmcyejun@zju.edu.cn Wu_hao@zju.edu.cn duqin@zju.edu.cn.
Qin DuDepartment of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China wzmcyejun@zju.edu.cn Wu_hao@zju.edu.cn duqin@zju.edu.cn.
Jun YeDepartment of Gastroenterology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang, China wzmcyejun@zju.edu.cn Wu_hao@zju.edu.cn duqin@zju.edu.cn.ORCID 0000-0002-0324-978X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMETHODS AND ANALYSIS: This is a single-centre, single-blind, randomised controlled trial, enrolling 855 patients with ETHICS AND DISSEMINATION: This study was approved by the Ethics Committee of Second Affiliated Hospital, School of Medicine, Zhejiang University (Number 20230103). The results will be published in the appropriate peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT05718609.

Indexed as

Anti-Infective AgentsHelicobacter InfectionsHelicobacter pyloriAmoxicillinBismuthChinaClarithromycinFurazolidoneHumansRabeprazoleRandomized Controlled Trials as TopicSingle-Blind MethodAmoxicillinAnti-Infective AgentsBismuthClarithromycinFurazolidoneRabeprazoleGastroenterologyGASTROENTEROLOGYMICROBIOLOGY

Identifiers

PMID37479526
PMCPMC10364167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.